Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study
With development partner support, introduction of HPVV, PCV and RVV may represent good value for money in Samoa, Tonga, Tuvalu and Vanuatu, depending on willingness to pay thresholds. However, inclusion of these three vaccines will place considerable burden on immunisation budgets. Financial sustainability requires increases in immunisation budgets and negotiation of affordable vaccine prices. This analysis provides evidence of the benefit of introducing new vaccines, but shows the importance of affordable pricing to ensure sustainability for small Pacific Island countries.
Authors
- Victoria Oliver (ORCID: https://orcid.org/0000-0002-7023-5329)
- Fiona M. Russell (ORCID: https://orcid.org/0000-0002-3077-9639)
- K. W. F. Lam (ORCID: https://orcid.org/0000-0002-9910-6088)
- R. Rabanal
- Clare Whelan
- Ross McLeod (ORCID: https://orcid.org/0000-0001-6232-1334)
- Inez Mikkelsen-Lopez
- Siale Akauola
- Emma Watts
- Natalie Carvalho
- Andrew Clark
- Murat Hakan Ozturk
- Mark Jit
- Kylie Jenkins
- Take Naseri
Institutions
- The University of Melbourne (AU)
- The Kids Research Institute Australia (AU)
- South Australian Research and Development Institute (AU)
- Ministry of Health (TO)
- London School of Hygiene & Tropical Medicine (GB)
- Asian Development Bank (PH)
- Murdoch Children's Research Institute (AU)
- Princess Margaret Hospital (TV)
- University of the South Pacific (FJ)
- New York University (US)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1371/journal.pmed.1004604
- Primary Topic
- Viral gastroenteritis research and epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00